[1] Hansen O, Sorensen P, Hansen K H. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period[J].Lung Cancer, 2010, 68(1):111
[2] Hute J P, Aylor E, Illiams J, et al. A metabolic study of patients with lung cancer and hyponatremia of malignancy[J]. Clin Cancer Res, 2006, 12(3):888
[3] Schwartz W B, Bennett W, Curelop S, et al. A syndrome of renal Sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone[J]. Am J Med, 1957, 23(4):529
[4] Misra U K, Kalita J, Bhoi S K, et al. A study of hyponatremia in tuberculous meningitis[J].J Neurol Sci, 2016, 367:152
[5] Maja Z, Piotr K, Jerzy K. Hyponatraemia-evaluation of prevalence in patients hospitalized in the Pulmonary Department and prognostic significance in lung cancer patients[R]. Praca Oryginalna, 2014, 82(1):18
[6] Berghmans T, Paesmans M, Body J J. A prospectivestudy on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis[J].Support Care Cancer, 2000, 8(3):192
[7] Fiordoliva I, Meletani T, Baleani M G, et al.Managing hyponatremia in lung cancer: latest evidence and clinical implications[J]. Ther Adv Med Oncol, 2017, 9(11):711
[8] Verbalis J G, Goldsmith S R, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations[J]. Am J Med, 2007, 120(11 Suppl 1):S1
[9] Chrier R W.Vasopressin and a quaporin 2 in clinical disorders of water homeostasi[J]. Semin Nephrol, 2008, 28(3):289
[10] Sun N H, Wang S H, Liu J N, et al. The productions of atrial natriuretic peptide and arginine vasopressin in small cell lung cancer with brain metastases and their associations with hyponatremia[J]. Eur Rev Med Pharmacol Sci, 2017,21(18):4104
[11] Aemkerian G P, Kerley W, Ogner P, et al. Small cell lung cancer[J]. JNCCN J Natl Compr Canc Netw, 2013, 11: 78
[12] Adulescu D, Bunea D, Pripon S, et al. Severe paraneoplastic hyponatremia and hypoosmolality in a patient with small-cell lung carcinoma:syndrome of inappropriate antidiuretic hormone secretion versus atrial natriuretic peptide or both[J].Clin Lung Cancer, 2007, 8(6):392
[13] Hoang M, Varughese J, Ratner E. Syndrome of inappropriate antidiuretic hormone after vinorelbine treatment[J]. Oncol Pharm Pract, 2013, 19(4):380
[14] Shereen E, Asmaa E M, Amaal G. Cyclophosphamide-induced symptomatic hyponatremia,a rare but severe side effect:a case report[J].Onco Targets Ther, 2014,30(7):1641
[15] Diskin C, Dansby L M, Radcliff L, et al. Recurrent hyponatremia after intrathecal methotrexate not related to antidiuretic hormone:is a natriuretic peptide activated[J]. Am J Med Sci, 2006, 331(1):37
[16] Kondo R, Watanabe S, Shoji S, et al. A phase II study of irinotecan for patients with previously treated Small-Cell lung cancer[J].Oncology, 2018,94(4):223
[17] Ma Y, Hou L,Yu F, et al. Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer[J].Oncotarget, 2016, 8(11):18417
[18] Berardi R, Santoni M, Rinaldi S, et al. Risk of hyponatraemia in cancer patients treated with targeted therapies:a systemmatic review and Meta-Analysis of clinical trials[J].PLoS One, 2016, 11(5):e0152079
[19] Harris T, Paul H, Claire E H, et al. Hyponatraemia secondary to nivolumab-induced primary adrenal failure[J].Endocrinol Diabetes Metab Case Rep, 2016, 2016.pil:16
[20] Torino F, Corsello S M, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors[J].Curr Opin Oncol, 2016,28(4):278
[21] Sejling A S, Thorsteinsson A, Eiken P. Recovery from SIADH-Associated osteoporosis: a case report[J]. J Clin Endocrinol Metab, 2014, 99(10):3527
[22] Selmer C, Madsen J C, Torp-Pedersen C, et al. Hyponatremia, all-cause mortality, and risk of cancer diagnoses in the primary care setting: A large population study[J]. Eur J Intern Med, 2016, 36:36
[23] Louise H B, Christian F C, Frede D, et al. Diagnosis of hyponatremia and increased risk of a subsequent cancer diagnosis: results from a nationwide population-based cohort study[J]. Acta Oncol (Madr), 2018, 57(4):522
[24] Yang Y P, Sun N H, Sun P, et al. Clinical characteristics and prognosis of elderly small cell lung cancer patients complicated with hyponatremia: a retrospective analysis[J]. Anticancer Res, 2017, 37(8):4681
[25] Tiseo M, But S, Boni L, et al. Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan[J].Lung Cancer, 2014, 86(1):91
[26] Jacot W, Colinet B, Bertrand D, et al. Quality of Life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients[J]. Ann Oncol, 2008,19(8):1458
[27] Gralla R J, Ahmad F, Blais J D, et al. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials[J]. Cancer Med, 2017, 6(4):723
[28] Vasudev N S, Brown J E, Brown S R, et al. Prognostic factors in renal cell carcinoma: Association of preoperative Sodium concentration with survival[J].Clini Cancer Res, 2008, 14(6):1775
[29] Tosh P, Rajan S, Kadapamannil D, et al. Efficacy of oral tolvaptan versus 3%hypertonic saline for correction of hyponatraemia in post-operative patients[J].Indian J Anaesth, 2017,61(12):996
[30] Peri A, Grohe C, Berardi R, et al. SIADH: differential diagnosis and clinical management[J]. Endocrine, 2017, 55(1):19
[31] Castillo J J, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients[J]. Oncologist, 2012,17(6):756
[32] Burst V, Grundmann F, Kubacki T A, et al. Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study[J]. Supportive Care in Cancer, 2017,25(7):2275
[33] Adrogue H J. Consequences of inadequate management of hyponatremia[J]. Am J Nephrol, 2005, 25(3):240
[1]李家腾,宋世辉,王 田,等.小细胞肺癌患者化疗前后CEA、NSE和CYFRA21-1的变化对评估预后的作用[J].天津医科大学学报,2014,20(06):448.
LI Jia-teng,SONG Shi-hui,WANG Tian,et al.Effect of Changes of CEA, NSE and CYFRA21-1 before and after chemotherapy on the evaluation of prognosis in patients with small cell lung cancer[J].Journal of Tianjin Medical University,2014,20(04):448.
[2]王子乔,张雪茜,孟凡荣,等.小鼠小细胞肺癌模型的建立[J].天津医科大学学报,2018,24(01):29.
WANG Zi-qiao,ZHANG Xue-xi,MENG Fan-rong,et al.Establishment of a mouse model of pulmonary small cell lung cancer[J].Journal of Tianjin Medical University,2018,24(04):29.
[3]张姝阳,张家丽,赵 宁,等.IP方案与CAO方案二线治疗复发小细胞肺癌的疗效及毒副作用比较研究[J].天津医科大学学报,2018,24(05):415.
ZHANG Shu-yang,ZHANG Jia-li,ZHAO Ning,et al.Comparison of the efficacy and toxicity between the IP regimen and the CAO regimen in the second line treatment for recurrent small cell lung cancer[J].Journal of Tianjin Medical University,2018,24(04):415.
[4]董傲然,张家丽,任秀宝,等.促胃泌素释放肽前体对小细胞肺癌的诊断价值[J].天津医科大学学报,2019,25(03):234.
DONG Ao-ran,ZHANG Jia-li,REN Xiu-bao,et al.Diagnosis value of pro-gastrin-releasing peptide precursor for small cell lung cancer[J].Journal of Tianjin Medical University,2019,25(04):234.
[5]赵军华,邱鸣寒,袁智勇.射波刀治疗小细胞肺癌脑转移的疗效分析[J].天津医科大学学报,2019,25(04):346.
ZHAO Jun-hua,QIU Ming-han,YUAN Zhi-yong.The effectiveness of CyberKnife for brain metastases from small cell lung cancer[J].Journal of Tianjin Medical University,2019,25(04):346.
[6]孙基峰,罗 婧,徐利明,等.广泛期小细胞肺癌肝转移治疗模式探讨[J].天津医科大学学报,2019,25(06):577.
SUN Ji-feng,LUO Jing,XU Li-ming,et al.Discussion on the treatment mode of liver metastasis in patients with extensive small cell lung cancer[J].Journal of Tianjin Medical University,2019,25(04):577.
[7]杨沛轩,农育新,陈闽霞,等.手术对广泛期小细胞肺癌患者生存的影响:基于SEER数据库的倾向得分匹配分析[J].天津医科大学学报,2021,27(01):36.
YANG Pei-xuan,NONG Yu-xin,CHEN Min-xia,et al.Effect of surgery on survival in patients with extensive small cell lung cancer:a SEER database-based propensity scores matching analysis[J].Journal of Tianjin Medical University,2021,27(04):36.